launches Yurpeak in India for obesity, type 2 diabetes Cipla Limited launched Yurpeak, a once-weekly injectable for obesity and type 2 diabetes, in India. Tirzepatide, available in six strengths via KwikPen, is an adjunct to diet and exercise for adults with obesity or type 2 diabetes. Yurpeak enters the market following DCGI approval, with Cipla distributing and Lilly manufacturing it at Mounjaro's price. Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations.